OBJECTIVES: Disability among long-term methamphetamine (MA) users is multifactorial. This study examined the additive adverse impact of human immunodeficiency virus (HIV) infection, a common comorbidity in MA users, on functional dependence. METHODS: A large cohort of participants (N = 798) stratified by lifetime MA-dependence diagnoses (ie, MA+ or MA-) and HIV serostatus (ie, HIV+ or HIV-) underwent comprehensive baseline neuromedical, neuropsychiatric, and functional research evaluations, including assessment of neurocognitive symptoms in daily life, instrumental and basic activities of daily living, and employment status. RESULTS: Independent, additive effects of MA and HIV were observed across all measures of functional dependence, independent of other demographic, psychiatric, and substance-use factors. The prevalence of global functional dependence increased in the expected stepwise fashion across the cohort, with the lowest rates in the MA-/HIV- group (29%) and the highest rates in the MA+/HIV+ sample (69%). The impact of HIV on MA-associated functional dependence was moderated by nadir CD4 count, such that polysubstance use was associated with greater disability among those HIV-infected persons with higher but not lower nadir CD4 count. Within the MA+/HIV+ cohort, functional dependence was reliably associated with neurocognitive impairment, lower cognitive reserve, polysubstance use, and major depressive disorder. CONCLUSIONS: HIV infection confers an increased concurrent risk of MA-associated disability, particularly among HIV-infected persons without histories of immune compromise. Directed referrals, earlier HIV treatment, and compensatory strategies aimed at counteracting the effects of low cognitive reserve, neurocognitive impairment, and psychiatric comorbidities on functional dependence in MA+/HIV+ individuals may be warranted.
OBJECTIVES:Disability among long-term methamphetamine (MA) users is multifactorial. This study examined the additive adverse impact of human immunodeficiency virus (HIV) infection, a common comorbidity in MA users, on functional dependence. METHODS: A large cohort of participants (N = 798) stratified by lifetime MA-dependence diagnoses (ie, MA+ or MA-) and HIV serostatus (ie, HIV+ or HIV-) underwent comprehensive baseline neuromedical, neuropsychiatric, and functional research evaluations, including assessment of neurocognitive symptoms in daily life, instrumental and basic activities of daily living, and employment status. RESULTS: Independent, additive effects of MA and HIV were observed across all measures of functional dependence, independent of other demographic, psychiatric, and substance-use factors. The prevalence of global functional dependence increased in the expected stepwise fashion across the cohort, with the lowest rates in the MA-/HIV- group (29%) and the highest rates in the MA+/HIV+ sample (69%). The impact of HIV on MA-associated functional dependence was moderated by nadir CD4 count, such that polysubstance use was associated with greater disability among those HIV-infectedpersons with higher but not lower nadir CD4 count. Within the MA+/HIV+ cohort, functional dependence was reliably associated with neurocognitive impairment, lower cognitive reserve, polysubstance use, and major depressive disorder. CONCLUSIONS:HIV infection confers an increased concurrent risk of MA-associated disability, particularly among HIV-infectedpersons without histories of immune compromise. Directed referrals, earlier HIV treatment, and compensatory strategies aimed at counteracting the effects of low cognitive reserve, neurocognitive impairment, and psychiatric comorbidities on functional dependence in MA+/HIV+ individuals may be warranted.
Authors: Krisann K Oursler; Joseph L Goulet; Stephen Crystal; Amy C Justice; Kristina Crothers; Adeel A Butt; Maria C Rodriguez-Barradas; Knachelle Favors; David Leaf; Leslie I Katzel; John D Sorkin Journal: AIDS Patient Care STDS Date: 2011-01 Impact factor: 5.078
Authors: Tilman Schulte; Eva M Mueller-Oehring; Margaret J Rosenbloom; Adolf Pfefferbaum; Edith V Sullivan Journal: Biol Psychiatry Date: 2005-01-01 Impact factor: 13.382
Authors: J Cattie; M J Marquine; K A Bolden; L C Obermeit; E E Morgan; D R Franklin; A Umlauf; J M Beck; J H Atkinson; I Grant; S P Woods Journal: J Subst Use Date: 2015-02-03
Authors: Gunes Avci; David P Sheppard; Savanna M Tierney; Victoria M Kordovski; Kelli L Sullivan; Steven Paul Woods Journal: Clin Neuropsychol Date: 2017-09-27 Impact factor: 3.535
Authors: Kaitlin B Casaletto; David J Moore; Steven Paul Woods; Anya Umlauf; J C Scott; Robert K Heaton Journal: Clin Neuropsychol Date: 2016-01-12 Impact factor: 3.535
Authors: Lisa C Obermeit; Jordan E Cattie; Khalima A Bolden; Maria J Marquine; Erin E Morgan; Donald R Franklin; J Hampton Atkinson; Igor Grant; Steven Paul Woods Journal: Addict Behav Date: 2013-08-19 Impact factor: 3.913
Authors: Jessica L Montoya; Anya Umlauf; Ian Abramson; Jayraan Badiee; Steven Paul Woods; J Hampton Atkinson; Igor Grant; David J Moore Journal: J Affect Disord Date: 2013-08-16 Impact factor: 4.839
Authors: Igor Grant; Donald R Franklin; Reena Deutsch; Steven P Woods; Florin Vaida; Ronald J Ellis; Scott L Letendre; Thomas D Marcotte; J H Atkinson; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; John A McCutchan; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Davey M Smith; Robert K Heaton Journal: Neurology Date: 2014-05-09 Impact factor: 9.910
Authors: María J Marquine; Jennifer E Iudicello; Erin E Morgan; Gregory G Brown; Scott L Letendre; Ronald J Ellis; Reena Deutsch; Steven Paul Woods; Igor Grant; Robert K Heaton Journal: Psychiatry Res Date: 2013-11-13 Impact factor: 3.222